ArticleCost effectiveness and resource allocation : C/E2026

Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis.

Basile Njei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.